FGFR2 and gastric cancer: The selective FGFR inhibitor AZD4547 is also under a randomized phase II trial comparing AZD4547 to paclitaxel as second line treatment of advanced GC and gastroesophageal junction (GEJ) cancer harboring FGFR2 amplification or polysomy (SHINE; ClinicalTrials.gov identifier: NCT01457846).